Product logins

Find logins to all Clarivate products below.


Dyslipidemia | Treatment Algorithms: Claims Data Analysis | Hypertriglyceridemia | US | 2019

Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the associated CV risk. Fibrates, statins, and omega-3 fatty acids are predominantly prescribed to manage hypertriglyceridemia patients. Using a longitudinal claims data analysis, we demonstrate how hypertriglyceridemia is being treated in the United States and provide insight into what is driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hypertriglyceridemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hypertriglyceridemia patients?
  • How has Vascepa been integrated into the hypertriglyceridemia treatment algorithm compared with the available generic omega-3 fatty acids?
  • What percentage of hypertriglyceridemia patients receive drug therapy within six months of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of hypertriglyceridemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated hypertriglyceridemia patients?

Geographies: United States

Real World Data: Longitudinal patient-level claims data analysis

Key Drugs Covered: Fibrates, omega-3-acid ethyl esters (Lovaza), Vascepa, statins, niacin derivatives

Key Analysis Provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…